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Abstract
Since Kaposi’s sarcoma-associated herpesvirus (KSHV or human herpesvirus 8) was first identified in Kaposi’s sarcoma (KS)
lesions of HIV-infected individuals with AIDS, the basic biological understanding of KSHV has progressed remarkably.
However, the absence of a proper animal model for KSHV continues to impede direct in vivo studies of viral replication,
persistence, and pathogenesis. In response to this need for an animal model of KSHV infection, we have explored whether
common marmosets can be experimentally infected with human KSHV. Here, we report the successful zoonotic
transmission of KSHV into common marmosets (Callithrix jacchus, Cj), a New World primate. Marmosets infected with
recombinant KSHV rapidly seroconverted and maintained a vigorous anti-KSHV antibody response. KSHV DNA and latent
nuclear antigen (LANA) were readily detected in the peripheral blood mononuclear cells (PBMCs) and various tissues of
infected marmosets. Remarkably, one orally infected marmoset developed a KS-like skin lesion with the characteristic
infiltration of leukocytes by spindle cells positive for KSHV DNA and proteins. These results demonstrate that human KSHV
infects common marmosets, establishes an efficient persistent infection, and occasionally leads to a KS-like skin lesion. This
is the first animal model to significantly elaborate the important aspects of KSHV infection in humans and will aid in the
future design of vaccines against KSHV and anti-viral therapies targeting KSHV coinfected tumor cells.
Citation: Chang H, Wachtman LM, Pearson CB, Lee J-S, Lee H-R, et al. (2009) Non-Human Primate Model of Kaposi’s Sarcoma-Associated Herpesvirus
Infection. PLoS Pathog 5(10): e1000606. doi:10.1371/journal.ppat.1000606
Editor: Scott Wong, Oregon Health & Science University, United States of America
Received June 19, 2008; Accepted September 8, 2009; Published October 2, 2009
Copyright:  2009 Chang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by U.S. Public Health Service grants CA082057, CA31363, CA115284, DE019085, RR00168, KICOS GRL, and a Hastings
Foundation grant. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: jaeujung@usc.edu
Introduction
The most recently described human tumor virus, KSHV is a c-2
herpesvirus and was first identified in association with KS, the
most common neoplasm amongst AIDS patients [1]. KS is
clinically separated into four different forms: classical KS, endemic
KS, iatrogenic KS, and epidemic HIV-associated KS [2]. In
addition to KS, KSHV is linked with two other cancers, Primary
effusion lymphoma (PEL) [1,3,4] and Multicentric Castleman’s
disease [5,6,7]. Both of these cancers are B cell proliferative
disorders, generally have poor outcomes, and have short me-
dian survival times complicated by their association with
AIDS.
One experimental barrier to working with KSHV has been the
lack of an in vitro system for examining lytic replication. While
KSHV can infect a wide variety of primary cells and cell lines,
none support the growth of KSHV to a high titer [8]. Typically,
viruses can be stimulated toward replication only through the
addition of agents like phorbol esters [9], this limitation extending
to the in vivo setting. These problems had previously been
addressed in two ways: through manipulation of the virus for
increased titer or cell infectivity and the use of highly related
viruses. By inserting a gene conferring resistance to an antibiotic,
one can select cell populations that are essentially 100% infected
[10]. Meanwhile, two examples of related viruses used as stand-ins
for KSHV are Herpesvirus saimiri (HVS) [11] and Rhesus
rhadinovirus (RRV) [12,13]. These viruses are largely co-linear
with KSHV, carry many of the same genes, and are known to
infect non-human primates [13]. RRV infection develops
abnormal cellular proliferations characterized as extranodal
lymphoma and retroperitoneal fibromatosis, a proliferative
mesenchymal proliferative lesion, in an experimentally co-infected
rhesus macaque with simian immunodeficiency virus, suggesting
an excellent primate model to investigate KSHV-like pathogenesis
[14,15]. In the case of HVS, infection of New World primates
results in an aggressive, fulminant lymphoma. However, HVS
primarily infects T cells, not B cells, as KSHV does. RRV persists
upon infection in rhesus macaques, infects B cells, and induces B
cell hyperplasia, but no KS-like disease occurs [15]. On the other
hand, murine Herpesvirus 68 (MHV-68) provides a small,
experimentally accessible mouse model, but its infection does not
associate with KS or related diseases [16]. The introduction of
KSHV genes into these systems has proven to be useful, albeit
limited, for the study of KSHV [17].
PLoS Pathogens | www.plospathogens.org 1 October 2009 | Volume 5 | Issue 10 | e1000606Besides these related virus models, in vitro experiments and
transgenic animal models have been the main forces in elucidating
the potential roles of individual KSHV proteins in cell culture and
mouse models, respectively [18,19,20,21]. In a recent study,
SCID-hu Thy/Liv mice reconstituted with the liver and thymus of
human fetuses were utilized to study viral transcription as well as
the susceptibility of the mice to infection with BCBL-1 derived
KSHV [19,22]. In addition, Parsons et. al have shown that NOD/
SCID mice infected with purified KSHV provide a system for
demonstrating latent and lytic viral gene expression in addition to
cell tropism [19,22]. Furthermore, they have investigated immune
responses to KSHV via implanted NOD/SCID mice reconstituted
with human fetal bone, thymus, and skin [19,22]. In spite of these
significant improvements, none of these models truly reflect the in
vivo setting. To understand the relative contributions of KSHV
proteins to the cellular activation of KSHV-associated diseases and
host-viral interactions for viral persistent infection, an animal
model that provides a complete viral infection in addition to latent
and lytic viral gene expression within the context of an intact host
immunity still needs to be developed. In this report, we describe
the efficient zoonotic transmission of KSHV into common
marmosets (Callithrix jacchus, Cj), a New World primate. Common
marmosets intravenously inoculated with recombinant KSHV
rapidly seroconverted and maintained high antibody responses for
over one and a half years. In addition, KSHV DNA and LANA
proteins were readily detectable in PBMCs and various tissues of
the infected marmosets at a variety of time points. Furthermore,
two common marmosets inoculated with rKSHV.219 by the oral
route seroconverted and were positive for viral DNA in their
PBMCs. Remarkably, a common marmoset infected with
rKSHV.219 via the oral route developed a KS-like lesion with
the characteristic spindle cells along with small blood vessels and
extravasated erythrocytes. These results demonstrate that human
KSHV effectively infects common marmosets, establishes persis-
tence, and occasionally associates with the development of KS-like
skin lesions. This is the first animal model of KSHV persistent
infection to allow for analyses of the molecular mechanisms of the
KSHV lifecycle directly in a non-human primate.
Results/Discussion
Experimental infection of common marmosets with
rKSHV.219
Given its magnitude as a human health problem, it is crucial to
understand the molecular details of KSHV biology. However, the
lack of an animal model of KSHV infection greatly hampers
studies of KSHV pathogenesis and persistence. Therefore, we
explored whether common marmosets can be experimentally
infected with human KSHV, and if so, to what extent
experimental infection recapitulates the important aspects of
KSHV infection. To facilitate the infection of common marmosets
with KSHV, we chose a recombinant KSHV, rKSHV.219, from
KSHV-infected JSC-1 cells [23]. rKSHV.219 expresses red
fluorescent protein (RFP) from the KSHV lytic PAN promoter,
green fluorescent protein (GFP) from the EF-1a promoter, and
contains the gene for puromycin resistance as a selectable marker
[10]. Two common marmosets (Cj15-05 and Cj16-05) were
inoculated intravenously with 5610
6 infectious units (IU) of
rKSHV.219. Blood samples were obtained at various time points
to measure the marmosets’ antibody responses and to detect viral
DNA and proteins. Both monkeys quickly seroconverted to anti-
KSHV-positive status within 20 days after inoculation (Fig 1A) and
the animals’ anti-KSHV antibodies persisted at very high levels for
over 1.5 years. In addition, the sera from both infected monkeys
readily reacted with purified KSHV virion proteins on immuno-
blots, with higher antibody reactivities detected over time (Fig 1B).
A positive control, immunoreactive serum from a KSHV-infected
patient was included to validate this immunoblot assay (Supple-
mental Fig S1). PBMCs from KSHV-infected animals were PCR-
positive for KSHV LANA and ORF9 10 and 20 days after
infection, respectively (Fig 1C and 1D). Viral DNA persisted in the
PBMCs of monkey Cj15-05 for the entire 1.5- year span the
animal was studied, whereas the level of viral DNA in monkey
Cj16-05 decreased after 200 days postinfection (Fig 1C). Real-time
PCR analysis indicated that the KSHV DNA copy number/mgo f
genomic PBMC DNA from the infected monkeys were substan-
tially lower than that of rKSHV.219-infected Vero cells (Fig 1D).
The low viral DNA copy number suggests that a minor population
of the monkey PBMCs carried the rKSHV.219 genome. This was
confirmed by confocal microscopy which showed that the KSHV
LANA protein was detected in monkey PBMCs at a frequency of
2–5 cells per 1610
6 cells (Fig 1E). It should be noted that this
figure depicts a rare positive field and does not reflect the overall
incidence of LANA-positive cells. However, the infection frequen-
cy is similar to that of other c-2 Herpesviruses, such as Rhesus
lymphocryptovirus, Rhesus rhadinovirus, and Herpesvirus
saimiri, which persist asymptomatically in their natural hosts
[11,12,15,24]. Due to the lack of an efficient in vitro culture system
for KSHV infection and replication, virus recovery from the
PBMCs of the experimentally infected marmosets was unsuccess-
ful. Nevertheless, these results unambiguously demonstrate
the persistent infection of naı ¨ve common marmosets by
rKSHV.219.
Analysis of CD20
+ B cells in the blood of the two infected
marmosets showed increased B cell populations when compared to
naı ¨ve marmosets (Fig 2). Although the total number of B cells did
not change significantly in the initial few months after infection
with rKSHV.219, their numbers noticeably increased around
seven months postinfection and remained relatively elevated for as
long as we followed these animals. Naı ¨ve common marmosets had
10–15% CD20
+ B cells in their PBMCs while rKSHV.219-
infected marmosets Cj15-05 and Cj16-05 had 15–20% CD20
+ B
cells (Fig 2 and Supplemental Fig S2). Interestingly, a 7 fold
Author Summary
Kaposi’s sarcoma-associated herpesvirus (KSHV or human
herpesvirus 8), the most recently identified human tumor-
inducing virus, has been linked to Kaposi’s sarcoma,
pleural effusion lymphomas and multicentric Castleman’s
disease. In fact, KSHV accounts for a large proportion of
the cancer deaths in Africa. Further, the incidence of KSHV
in the US and Europe has greatly increased due to the AIDS
pandemic. Despite these pressing human health problems,
studies of KSHV infection are greatly hampered by the lack
of cell culture and animal models. To address this serious
need, we set out to develop an animal model for KSHV
infection. In this manuscript, we report the successful
zoonotic transmission of KSHV into common marmosets
(Callithrix jacchus, Cj), a New World primate. Our study
demonstrates that experimental KSHV infection of the
common marmoset is highly analogous to its infection of
humans, including the means of infection, sustained
serological responses, latent infection of PBMCs, virus
persistence, and KS-like skin lesion development, although
the latter was infrequent in experimental KSHV infections.
This model thus provides a unique opportunity to dissect
the molecular mechanisms of KSHV infection, persistence,
and pathogenesis directly in primates.
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2 CD20
+ B cells at 200 days postinfection
was observed in marmosets infected with rKSHV.219 (Fig 1F) and
this population was maintained until these animals were
euthanized (data not shown), indicating that rKSHV.219 infection
leads to elevated levels of CD20
+ B cells in marmosets. However,
no B cell hyperplasia was observed in either monkey (data not
shown).
Early infection of rKSHV.219 in common marmoset
To detect early KSHV infection, a marmoset (Cj325-04) was
sacrificed 21 days after intravenous inoculation with 5610
6 IU of
rKSHV.219. An enzyme-linked immunosorbent assay (ELISA)
showed a strong anti-KSHV antibody response (Fig 3A) while
PCR products from a variety of tissues to test the presence of
KSHV LANA DNA were yielded positive results only for samples
from the jejunum and liver (Fig 3B). PBMCs were collected at the
time of sacrifice and cultured in vitro for one week. Approximately
1/10
4–5 lymphocytes were GFP-positive and RFP-negative,
suggesting latent KSHV infection (Fig 3C). In addition, the
KSHV LANA latency-associated protein was readily detected in
PBMCs of the rKSHV.219-infected marmoset (Fig 3D). Taken
together, these results indicate that KSHV rapidly establishes
latent infection in common marmoset PBMCs. It should be noted
that the GFP-positive signal from PBMCs of infected marmosets
disappeared after an additional week of incubation in vitro (data
not shown). Due to a low frequency of GFP-positive cells,
however, it is unclear whether the GFP-positive cells died or lost
the viral genome after a week of incubation in vitro. This suggests
that while GFP is a convenient marker for viral infection, its use
may be limited to the early phase of KSHV infection in
marmosets.
Figure 1. Experimental infection of common marmosets with rKSHV.219. (A) ELISA using the sera (1:100 dilution) of infected marmosets
(Cj15-05 and Cj16-05) against the lysed recombinant virus. The results show the averages of four repeats and standard deviations. These assays were
reproduced by at least four independent occasions. (B) Immunoblot using the sera of infected marmosets (Cj15-05 and Cj16-05). Sera (1:500 dilution)
taken from naı ¨ve control marmosets (Control) and infected marmosets (Cj15-05 and Cj16-05 in the left panel and Cj15-05 in the right panel) at various
time points were used to immunoblot 20 mg of purified virion proteins. P.I., days postinfection. (C and D) Real-time PCR analyses of KSHV LANA and
ORF9 DNA. Purified genomic DNA (100 ng) from the PBMCs of three naı ¨ve controls and two infected (Cj15-05 and Cj16-05) marmosets was used for
real time-PCR with primers specific for LANA (c) and ORF9 (D). Purified genomic DNA (100 ng) from Vero.rKSHV.219 cells was included as a control (P)
in (C). DNA copy number was calculated using a standard curve with pcDNA3-ORF9 DNA and presented as the viral copy number per mg of DNA. M,
100-bp DNA molecular markers. The results show the averages of four repeats and standard deviations. (E) Detection of the LANA protein by confocal
microscopy. The PBMCs of KSHV-infected marmosets were subjected to immunostaining with anti-LANA, followed by confocal microscopy. The
arrows indicate LANA-positive cells. The top panels show phase contrast images of the PBMCs. The scale bars represent 20 mm. It should be noted
that this picture shows an example of a rare positive field, but not reflecting the overall incidence of LANA positive cells.
doi:10.1371/journal.ppat.1000606.g001
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treatment
In transplant recipients, immune suppression is thought to
disturb the host’s surveillance of KSHV, leading to viral
reactivation and an increased systemic viral load [2]. In contrast,
rapamycin, an immunosuppressive drug, reduces KSHV-infected
PEL cell growth in culture [25] and inhibits the progression of
dermal KS in kidney transplant recipients while providing effective
immunosuppression [26]. To investigate the direct impact in vivo of
an immunosuppressive agent on persistent KSHV infection, two
common marmosets (Cj333-04 and Cj139-04) were treated with
FK506 (Tacrolimus or Fujimycin, 100 mg/kg/day) immunosup-
pressive drug [27] for 14 days prior to intravenous inoculation
with 5610
6 IU of rKSHV.219, with treatment continuing for an
additional 100 days. Immune-suppressed monkeys inoculated with
rKSHV.219 seroconverted to anti-KSHV-positive status within 14
days after inoculation (Fig 4A). Although the anti-KSHV response
and KSHV DNA remained present 100 days after infection, they
were of a considerably lower magnitude than those of immune-
competent monkeys. Compared to untreated animals Cj15-05 and
Cj16-05, FK506-treated monkeys Cj333-04 and Cj139-04 showed
anti-KSHV antibody responses approximately 2–3 fold lower
throughout at 40–80 days postinfection, a shorter duration of time
when a positive KSHV LANA DNA signal could be obtained by
PCR, and substantially lower copy numbers (Fig 4B). To assess the
tissue distribution of rKSHV.219 in infected marmosets, KSHV
LANA-specific DNA was amplified from various tissues and
organs of immune-competent and immune-suppressed common
marmosets. rKSHV.219 DNA was readily detected in numerous
tissues of infected monkeys Cj15-05 and Cj16-05, including the
tonsils, tongue, lymph nodes, spleen, jejunum, lungs, colon, liver,
thymus, submandibular salivary gland, inguinal skin, and bone
marrow (Fig 5). In contrast, only the submandibular lymph nodes
and bone marrow were positive for rKSHV.219 DNA in FK506-
treated animals Cj333-04 and Cj139-04 (Fig 5). These results
indicate that immunosuppressive drug treatment leads to a
significant reduction of persistent KSHV infection in vivo.
Oral infection of common marmosets with rKSHV.219
Two common marmosets were orally inoculated with 5610
7 IU
of rKSHV.219. Both monkeys inoculated with rKSHV.219
quickly seroconverted to anti-KSHV-positive status within 20
days after inoculation (Fig 6A). However, the anti-KSHV response
was much lower in orally infected marmosets than in intravenously
infected marmosets and persisted for a shorter period of time
(Fig 6A). PBMCs from KSHV-infected marmosets Cj10-05 and
Cj11-05 collected on day 41 postinfection were positive for the
KSHV LANA sequence but we could not detect KSHV LANA
DNA in the PBMCs at any other time under the same conditions
(Fig 6B). Like the intravenously infected marmosets, the KSHV
Figure 2. Increase in CD20
+ B cell populations in common marmosets infected with rKSHV.219. PBMCs from Cj15-05 and Cj16-05 at day
210 P.I. were used for flow cytometry analysis with anti-CD3, anti-CD20, and anti-HLA-DR to identify T cells, B cells, and activated lymphocytes,
respectively. The PBMCs from uninfected marmosets Cj538-03 and Cj537-03 were used as controls. The numbers in the boxes indicate percentages
relative to the entire PBMC population.
doi:10.1371/journal.ppat.1000606.g002
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marmosets (Fig 6C). However, since the efficiency of oral infection
was much lower than that of intravenous infections, the detection
frequency and time period of LANA positivity via confocal
microscopy was much lower and more limited with oral infection
compared to that in intravenous infection. These results indicate
that KSHV infects common marmosets through the oral route but
as seen with other viruses [24], oral infection of KSHV is not as
efficient as intravenous infection in common marmosets.
Remarkably, one (Cj10-05) of two animals orally infected with
KSHV developed a skin lesion on its ventral abdomen at 41 days
postinfection (Fig 7A). This purple skin lesion was approximately
1.5 cm in diameter and had similar histopathological features to
those observed in AIDS-associated KS lesions. Histological
examination of a biopsy revealed a nonencapsulated dermal mass
with characteristics typical of KS lesions. Pleomorphic spindle cells
arranged in short bundles were observed, along with small blood
vessels and extravasated erythrocytes (Fig 7B and C). The spindle
cells had a high mitotic index and had infiltrated into the
surrounding soft tissues (Fig 7B and C). Additionally, this KS-like
lesion of Cj10-05 was PCR-positive for the KSHV LANA
sequence (Fig 7D). Immunohistochemistry with antibodies against
LANA, vIL-6, and K8.1 detected KSHV LANA, vIL-6, and K8.1,
respectively, in the skin lesion (Fig 7E and F and Supplemental Fig
S3). The anti-KSHV LANA, anti-vIL-6, and anti-K8.1 reactivities
were specific, and no staining was observed with these antibodies
in control skin tissues from naı ¨ve common marmosets or in the
biopsy tissue of Cj10-05 when the antibodies were replaced with
isotype-matched irrelevant antibodies (data not shown and
Supplemental Fig S3). Moreover, immunohistochemistry showed
virtually identical phenotypes for the skin lesion on Cj10-05 and
human KS lesions (table in Fig 7 and Supplemental Fig S4). These
results collectively demonstrate that a common marmoset orally
infected with KSHV can develop a skin lesion with similar
histopathological features to those seen in human KS lesions and is
also positive for KSHV DNA and proteins. However, the intensity
and prevalence of LANA positive staining within the KS-like
lesion of Cj10-05 were not as strong or widespread as those of
human KS lesions. In addition, the expression of vIL-6 and K8.1
was restricted to a few cells in the KS-like lesion of Cj10-05, the
question of whether these cells were latently infected or lytically
replicated requiring further study.
Previous studies have illustrated the persistent infection of rhesus
macaque monkeys infected with RRV, a primate homolog of
KSHV [15,28]. Macaques inoculated with RRV alone display
transient viremia followed by a vigorous anti-RRVresponse withno
specific clinical features. In contrast, experimental RRV infection of
SIV-infected rhesus macaques induces some of the hyperplastic B
cell lymphoproliferative diseases which manifest themselves in
AIDS patients coinfected with KSHV [15]. Furthermore, cotton-
Figure 3. The early infection of rKSHV.219 in common marmoset. (A) Anti-KSHV ELISA with sera from Cj325-04 (1:100 dilution) was
performed as described in Figure 1A. The results show the averages of two repeats and standard deviations. These assays were reproduced by three
independent occasions. (B) The PCR products of KSHV DNA from various tissues of infected marmoset Cj325-04 at day 21 P.I. (C) Immunofluorescence
and differential interference contrast microscopy [34] of PBMCs from Cj325-04 at day 21 P.I. The scale bars represent 30 mm. It should be noted that
this picture shows an example of a rare positive field, but not reflecting the overall incidence of GFP-positive cells. (D) The PBMCs of the KSHV-
infected marmoset (day 21 P.I.) were subjected to immunostaining with anti-KSHV LANA. The pictures presented here are representative of multiple
immunofluorescence (top panel) and phase contrast (the bottom panel) images of the PBMCs from Cj325-04 at 21 P.I. The scale bars represent 2 mm.
doi:10.1371/journal.ppat.1000606.g003
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virus (EBV) develop diffuse malignant lymphomas resembling
human reticulum cell or immunoblastic sarcomas [29,30]. Addi-
tionally, Rhesus lymphocryptovirus, which is very similar to EBV
and naturally endemic in rhesus monkeys, can efficiently infect
naı ¨ve animals orally, with the resulting infection closely mimicking
key aspects of human EBV infection [31]. Our study demonstrates
that experimental KSHV infection of the common marmoset is
highly analogous to its infection of humans, including the means of
infection, atypical lymphocytosis, sustained serological responses,
latentinfectionofPBMCs,andvirus persistence.However, itshould
be noted while one of two KSHV-infected marmosets developed
KS-like lesion, the number of marmosets used for this experiment is
too low to reach the specific conclusion of the frequency of KS-like
lesion development induced by KSHV infection. Additional
extensive experiments with different conditions such as various
KSHV strains and titers and co-infection with HIV-1 or EBV may
be able to increase the incidence of KS development. Nevertheless,
this model thus provides a unique opportunity to dissect the
molecular mechanisms of KSHV infection, persistence, and
pathogenesis directly in primates.
We have found that FK506 immunosuppressive drug treatment
leads to a significant reduction of persistent KSHV infection in vivo.
Zoeteweij et al demonstrated that cyclosporine and FK506,
specific inhibitors of calcineurin-dependent signal transduction,
effectively block the in vitro KSHV reactivation induced by
ionomycin and thapsigargin, activators of intracellular calcium
mobilization [27]. This indicates that FK506 immunosuppressive
drug treatment may directly block KSHV reactivation in vivo or
suppress lymphocyte activation at an early stage of infection,
indirectly affecting KSHV persistent infection. Additional exper-
iments, e.g. the timing and type of immune suppression, are
necessary to determine the role of host immune competence in the
establishment of KSHV persistent infection.
Figure 4. Persistent rKSHV.219 infection is reduced by FK506 treatment. (A) ELISA using the sera (1:100 dilution) of infected, FK506-treated
common marmosets (Cj333-04 and Cj139-04) against the lysed recombinant virus. The results show the averages of two repeats and standard
deviations. These assays were reproduced by two independent occasions. (B) Detection of KSHV DNA from FK506-treated, rKSHV.219-infected
common marmosets Cj333-04 and Cj139-04. Genomic DNA (100 ng) purified from the PBMCs of FK506-treated marmosets Cj333-04 and Cj139-04
were used for real-time PCR reactions with LANA-specific primers. Genomic DNA from Vero.rKSHV.219 cells (P) was included as a control and the viral
DNA copy number/mg of DNA calculated using a standard curve with pcDNA3-LANA DNA. M, 100-bp DNA molecular markers. The results show the
averages of two repeats and standard deviations.
doi:10.1371/journal.ppat.1000606.g004
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that c-herpesviruses are nearly ubiquitous, with homologs of each
virus found in a number of different species [32]. Infection of a
naı ¨ve, natural host by these viruses usually results in a persistent
infection that rarely progresses to a pathogenic event outside of
specific clinical events. In contrast, cross-species transmission of
these viruses can result in profound diseases. For example,
herpesvirus saimiri (HVS) is a natural virus of squirrel monkeys,
found in over 90% of animals in captivity with no observable
pathogenesis [11]. However, transmission of HVS to common
marmosets results in a fatal, lymphoproliferative disorder with
100% efficiency. In addition, the transmission of RRV into
common marmoset was clear in regard to persistent infection,
although it was less conclusive with regards to pathogenicity
(unpublished results). Furthermore, viruses could be re-isolated
from this animal at multiple time points throughout the
experiment (unpublished results). Thus, it is intriguing that the
common marmoset is highly susceptible to infection by various
pathogens. We speculate that the limited major histocompatibility
complex class I (MHC I) polymorphism of common marmosets
may contribute to their susceptibility to KSHV infection and
pathogenesis. Extensive polymorphism of the MHC is thought to
confer immune protection on populations. Restriction fragment
length polymorphism analysis showed that there were a limited
number of common marmoset MHC class I alleles, whereas the
MHC class II gene loci were polymorphic. This may play a role in
the susceptibility of this New World primate species to a variety of
pathogens. In summary, this is the first animal model that
significantly recapitulates the important aspects of KSHV infection
in humans and will greatly aid the future designing of anti-viral
therapies and be of use in the development of vaccines against
KSHV.
Materials and Methods
Animals and housing
All common marmosets (Callithrix jacchus, Cj) were housed at the
New England Primate Research Center (NEPRC) in accordance
with the standards of the American Association for Accreditation
of Laboratory Animal Care and Harvard Medical School’s
Internal Animal Care and Use Committee. Common marmosets
experimentally inoculated with rKSHV.219 were individually
housed in bio-level 3 containment facilities.
Viral inoculations
Vero cells carrying rKSHV.219 were stimulated with trichos-
tatin A (TSA), the supernatants were harvested to purify
rKSHV.219, and the virus titer was determined in 293A and
Vero cells by performing a GFP-positive infection assay as
described [10]. In order to produce the virus, Vero cells carrying
rKSHV.219 were stimulated with 75 nM of TSA for 24 hrs, the
media changed, and grown for an additional 48 hrs in DMEM
media without FBS. To harvest the virus, the cells were pelleted at
2000 rpm for 10 min with Sorvall SW40 rotor and the ensuing
Figure 5. Tissue distribution of viral LANA DNA in rKSHV.219-infected common marmosets. Genomic DNA purified from tissue samples
of immune-competent Cj15-05 and Cj16-05 and FK506-treated Cj333-04 and Cj139-04 were used for real-time PCR with LANA-specific primers. Mid,
middle; Dis, distal; Prox, proximal; Buccal Muc, buccal mucosa; SubMSG, submandibular salivary gland; ING LN, inguinal lymph node; AxLN, auxiliary
lymph node; SubmLN, submandibular lymph node; MesLN, mesenteric lymph node; Parotid SG, parotid salivary gland; ING Skin, inguinal skin. Marker,
100-bp DNA molecular markers. The results show the averages of two repeats and standard deviations.
doi:10.1371/journal.ppat.1000606.g005
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centrifuged at 18000 rpm for 3 hrs with Sorvall SA-600 rotor to
concentrate rKSHV.219. 5610
6 IU of this rKSHV.219 was then
used to intravenously inoculate the marmosets, for which a
flexible, small-bore orogastric tube was utilized to slowly deliver
the viral inoculum to the caudal aspect of the oral cavity, tonsils,
and nostril mucosa. The inoculum (5610
7 IU of rKSHV.219) was
dripped slowly over the oral mucosa while the animal was under
light sedation, whereby the swallow reflex was maintained. The
animals were given ketamine (10–20 mg/kg body weight)
intramuscularly prior to blood sampling, inoculation, and
euthanasia. The animals underwent periodic blood sampling for
viral isolation attempts and the detection of viral DNA. The
animals were maintained until the termination of the study or
when any of the conditions for euthanasia were met.
Antibody responses
rKSHV.219 was purified from Vero.rKSHV.219 cells and lysed
with a 1% Triton X-100 buffer, after which it was put through five
cycles of freezing in liquid nitrogen followed by thawing. The
virion proteins were coated onto plates and used to detect reactive
antibodies by ELISA as described [12,28].
Clinical evaluation, biopsies, and blood samples
Following experimental rKSHV.219 inoculation, all animals
were examined daily. Body temperature and clinical data were
recorded via an implanted microchip and transponder (Bio Medic
Data Systems, Maywood, NJ). PBMCs were obtained prior to
inoculation and at various time points throughout the study.
Tissues were fixed in 10% neutral-buffered formalin and snap-
frozen at 270uC. Blood was obtained at various time points to
quantify the viral antibody response, viral load, and complete
blood count.
Histopathology, immunohistochemistry, and confocal
microscopy
Formalin-fixed, paraffin-embedded, and snap-frozen tissues
were used in immunohistochemical procedures to define the
immunophenotype of cells within the skin lesion tissue as described
[28]. Briefly, tissue sections were fixed in 2% paraformaldehyde
and immunostained with an avidin-biotin-horseradish peroxidase
complex technique with diaminobenzidine chromogen. The
primary antibodies used in this study were anti-CD20 (B1), anti-
CD8 (DK25), anti-CD3 (Nu-Th/1), anti-HLA-DR (CR3/43),
anti-Ki67 (MIB-1), anti-vWF (A00082), anti-vimentin (3B4), and
Figure 6. Oral infection of common marmosets with rKSHV.219. (A) Anti-KSHV ELISA using the sera of Cj10-05 and Cj11-05 (1:5 dilution) was
performed as described in Figure 1A. The results show the averages of two repeats and standard deviations. These assays were reproduced by four
independent occasions. (B) Real-time PCR of genomic DNA (100 ng) taken from orally infected marmosets Cj10-05 and Cj11-05 using LANA-specific
primers at various time points. Purified genomic DNA from Vero.rKSHV.219 cells (P) was included as a positive control. The viral DNA copy number/mg
of DNA was calculated using a standard curve with pcDNA3-LANA DNA. The results show the averages of two repeats with standard deviations. (C)
Detection of the LANA protein by confocal microscopy. PBMCs from orally infected marmosets Cj10-05 and Cj11-05 were subjected to
immunostaining with an anti-LANA antibody, followed by confocal microscopy. The scale bars represent 2 mm.
doi:10.1371/journal.ppat.1000606.g006
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LANA (clone 4A4) and vIL-6 were obtained from Advanced
Biotechnologies Inc. (Columbia, MD). Confocal microscopy was
used to define the immunophenotypes of virus-infected cells
among the PBMCs.
Detection of rKSHV.219 sequences
To test for the presence of rKSHV.219, DNA was extracted
from PBMCs or fresh frozen tissues using a QIAmp tissue kit
(Qiagen, Valencia, CA) according to the manufacturer’s instruc-
tions. DNA was eluted in 50 to 100 ml of sterile water treated with
diethylpyrocarbonate and PCR was performed as described
below. PBMCs were separated from the whole blood of infected
common marmosets using standard Ficoll isolation techniques as
described by the manufacturer (Organon Teknika, Malvern, PA).
Real-time PCR was performed with genomic DNA isolated from
the PBMCs or tissues of the infected animals and specific primers
based on previous analyses of the KSHV sequence [33]. LANA-
specific primers [forward primer (59-CCT CCA TCC CAT CCT
GTG TC-39) and backward primer (59-GGA CGC ATA GGT
GTT GAA GAG-39)] were used to generate a 146-bp product for
LANA detection. ORF9-specific primers [forward primer (59-ATT
CAA GGT CAT ATA CGG CG-39) and backward primer (59-
CTG GACAAA ACG ACAGGC TG-39)] were used to generate a
262-bp product for ORF9 detection. Amplification was performed
at 95uC for 25 s and 67.5uC for 60 s for 45 cycles in an iCycler
thermal cycler system (Bio-Rad, CA). Data was obtained at CT
values as per the manufacturer’s guidelines (the cycle number at
which logarithmic PCR plots cross a calculated threshold line). The
PCR products were resolved on a 3% ethidium bromide-stained
agarose gel and sequenced to confirm the identities of the KSHV
LANA and ORF9 gene fragments.
Immunoblot analysis
As described in the section ‘‘Antibody responses,’’ virion
particles were prepared by stimulating Vero.rKSHV.219 cells
with TSA, then by freezing and thawing rKSHV.219 a total of five
times in a 1% Triton X-100 buffer using liquid nitrogen. Purified
virion proteins (20 mg) were resolved by SDS-polyacrylamide gel
electrophoresis (PAGE) and transferred onto a PVDF membrane
(Bio-Rad). Immunodetection was achieved with 1:500 diluted
monkey sera. The proteins were visualized by a chemilumines-
cence reagent (Pierce) and detected by a Fuji chemiluminometer.
Flow cytometry analysis
5610
5 cells per sample were washed with PBS medium
containing 1% fetal calf serum and incubated with either
fluorescein isothiocyanate-conjugated (FITC) or phycoerythrin-
conjugated (PE) monoclonal antibodies for 30 min at 4uC. After
washing, each sample was fixed with a 2% paraformaldehyde
solution and flow cytometry analysis was performed with a FACS
Scan (Becton Dickinson Co.).
Supporting Information
Figure S1 Immunoblot using the KSHV-infected human sera.
KSHV-infected human sera and normal human sera (1:500
dilution) were used to immunoblot 20 mg of purified virion
proteins.
Found at: doi:10.1371/journal.ppat.1000606.s001 (0.30 MB TIF)
Figure 7. Development of a KS-like skin lesion on an orally infected common marmoset. (A) Skin lesion of rKSHV.219-infected marmoset
Cj10-05. (B and C) Histological examination of a marmoset Cj10-05biopsy shows a nonencapsulated dermal mass with characteristics typical of KS
lesions, pleomorphic spindle cells along with small blood vessels and extravasated erythrocytes. The spindle cells had a high mitotic index and had
infiltrated into the surrounding soft tissues. (D) Real-time PCR of the KS-like skin lesion tissue. Purified genomic DNA (100 ng) from the skin biopsies
of two control marmosets and the KS-like lesion of Cj10-05 were used for real time-PCR with LANA-specific primers. Purified genomic DNA from
Vero.rKSHV.219 cells was included as a positive control. The viral DNA copy number/mg of DNA was calculated using a standard curve with pcDNA3-
LANA DNA. The results show the averages of two repeats with standard deviations. (E and F) Immunohistochemistry of the KS-like skin lesion of
Cj10-05 with anti-LANA (E) and anti-vIL-6 (F). The insets in (E) and (F) show the LANA staining of human KS tissue and the vIL-6 staining of KSHV-
infected MCD, respectively. The scale bars represent 2 mm (B), 5 mm (C), and 20 mm (E and F). The table on the right is a summary of the results from
immunohistochemistry studies of a human KS lesion and the KS-like skin lesion of Cj10-05.
doi:10.1371/journal.ppat.1000606.g007
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marmosets infected with rKSHV.219. PBMCs from Cj15-05 (days
210, 320, 380 and 400 P.I.) and Cj16-05 (days 210, 260, 300 and
320 P.I.) were used for flow cytometry analysis with anti-CD3,
anti-CD20, and anti-HLA-DR to identify T cells, B cells, and
activated lymphocytes, respectively. Uninfected marmosets
(Cj190-98, Cj170-04, Cj60-00 and Cj54-05) served as the controls
in this experiment. The numbers in the boxes indicate percentages
relative to the entire PBMC population.
Found at: doi:10.1371/journal.ppat.1000606.s002 (1.27 MB TIF)
Figure S3 Immunohistochemistry of the KS-like skin lesion of
Cj10-05 with an anti-K8.1 antibody. The inset in the left panel
shows an enlarged view of the anti-K8.1 staining of the KS like
lesion of Cj10-05. Irrelevant control tissue (right top panel) and
KSHV-infected MCD (right bottom panel) were included as
negative and positive controls, respectively, for anti-K8.1 staining.
Found at: doi:10.1371/journal.ppat.1000606.s003 (5.70 MB TIF)
Figure S4 Immunophenotypic comparison of marmoset neo-
plasm and human KS lesions. Marmoset (A, C, E, G, and I; insert:
marmoset positive tissue control) and human tissues (B, D, F, H,
and J) were compared immunophenotypically using an ABC
immunostaining technique and DAB chromogen for vWF (A, B),
vimentin (C, D), desmin (E, F), HAM56 (G, H), and CD3 (I, J).
The proliferating spindle cells, stroma, and infiltrating inflamma-
tory cells showed similar immunophenotypic properties. The
tumors were composed primarily of vWF-negative, desmin-
negative, and vimentin-positive cells supported by a variable
stroma containing vWF-positive blood vessels and vimentin-
positive cells. Desmin reactivity was observed in the surrounding
tissues. Both tumors were infiltrated by HAM56-positive macro-
phages and significant numbers of CD3-positive lymphocytes.
Spindleoid cells were uniformly negative for these markers.
Found at: doi:10.1371/journal.ppat.1000606.s004 (8.07 MB TIF)
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